Strides mulls sell-off of pharma unit amid evolving strategic gameplan
This article was originally published in Scrip
Executive Summary
Strides Arcolab's reported plan to divest part of its business while focusing on its injectables arm could help the Indian firm pare debt, though analysts say that the company needs to ensure stability in its strategy in the longer term to boost growth.